Skip to content

Author

G. Curigliano

We have 5 of 861 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study.

BACKGROUND Folate receptor alpha (FRα) is overexpressed in most high-grade ovarian cancers (HGOC), but use of the FRα-targeting drug mirvetuximab soravtansine-gynx (MIRV) is limited by expression-level restrictions and toxicity profile. Sofetabart mipitecan (Sofe-M) is a novel FRα-targeting antibody-drug conjugate desi...

I. Ray-Coquard, D. O'Malley, A. Oaknin et al. · 0 citations
Review Sep 2026

Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel.

BACKGROUND The management of metastatic castration-resistant prostate cancer (mCRPC) after progression on androgen receptor pathway inhibitors (ARPI) and docetaxel presents a critical therapeutic choice between cabazitaxel and [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT). This review provides a comprehensive analy...

F. Mattana, E. Palesandro, Valentino Dragonetti et al. · 0 citations
Open access Sep 2026

Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial

Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...

Davide Ciardiello, G. Martini, L. Boscolo Bielo et al. · 0 citations
Review Open access Sep 2026

p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications.

The biological function of p53, its role in EGFR-mutant lung cancer, and the implications for current and future therapies are discussed, and a timely and cohesive synthesis of a rapidly evolving field is offered.

J. Etessami, I. Attili, P. T. Aliaga et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.